Journal of Cardiac Failure
Volume 14, Issue 4 , Pages 267-275 , May 2008

The Effects of Nesiritide on Renal Function and Diuretic Responsiveness in Acutely Decompensated Heart Failure Patients With Renal Dysfunction

  • Theophilus E. Owan, MD

      Affiliations

    • Mayo Clinic College of Medicine, Division of Cardiovascular Diseases
    • ,
  • Horng H. Chen, MB, BCH

      Affiliations

    • Mayo Clinic College of Medicine, Division of Cardiovascular Diseases
    • ,
  • Robert P. Frantz, MD

      Affiliations

    • Mayo Clinic College of Medicine, Division of Cardiovascular Diseases
    • ,
  • Barry L. Karon, MD

      Affiliations

    • Mayo Clinic College of Medicine, Division of Cardiovascular Diseases
    • ,
  • Wayne L. Miller, MD

      Affiliations

    • Mayo Clinic College of Medicine, Division of Cardiovascular Diseases
    • ,
  • Richard J. Rodeheffer, MD

      Affiliations

    • Mayo Clinic College of Medicine, Division of Cardiovascular Diseases
    • ,
  • David O. Hodge, MS

      Affiliations

    • Division of Biostatistics, Rochester, Minnesota
    • ,
  • John C. Burnett Jr., MD

      Affiliations

    • Mayo Clinic College of Medicine, Division of Cardiovascular Diseases
    • ,
  • Margaret M. Redfield, MD

      Affiliations

    • Mayo Clinic College of Medicine, Division of Cardiovascular Diseases
    • Corresponding Author InformationReprint requests: Margaret M. Redfield, MD, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905.

Received 27 April 2007 ,Revised 26 November 2007 ,Accepted 10 December 2007.

References 

  1. Krumholz HM, Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD, et al. Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. Am J Cardiol. 2000;85:1110–1113
  2. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J. 1999;138(2 Pt 1):285–290
  3. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61–67
  4. Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136–141
  5. Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?. J Card Fail. 2003;9:13–25
  6. NHLBIWorkingGroup. Cardio-Renal Connections in Heart Failure and Cardiovascular Disease. Available at: http://www.nhlbi.nih.gov/meetings/workshops/cardiorenal-hf-hd-htm. Accessed November 7, 2005.
  7. Nesiritide package insert. Scios, Inc., 1999–2008. Available at: http://www.sciosinc.com/pdf/natrecorpi_final.pdf. Accessed May 12, 2006.
  8. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–328
  9. Munagala VK, Burnett JC, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol. 2004;29:707–769
  10. Chen HH, Burnett JC. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians. 1999;111:406–416
  11. Houben AJ, van der Zander K, de Leeuw PW. Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology. Fundam Clin Pharmacol. 2005;19:411–419
  12. Schreiner GF, Protter AA. B-type natriuretic peptide for the treatment of congestive heart failure. Curr Opin Pharmacol. 2002;2:142–147
  13. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491
  14. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett J. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976–982
  15. Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006;47:345–353
  16. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, Schirger JA, Tsuruda T, Heublein DM, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation. 2004;109:1680–1685
  17. Luchner A, Stevens TL, Borgeson DD, Redfield MM, Bailey JE, Sandberg SM, et al. Angiotensin II in the evolution of experimental heart failure. Hypertension. 1996;28:472–477
  18. Redfield MM, Aarhus LL, Wright RS, Burnett JC. Cardiorenal and neurohumoral function in a canine model of early left ventricular dysfunction. Circulation. 1993;87:2016–2022
  19. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42:1050–1065
  20. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest. 1999;59:1–8
  21. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44:1049–1060
  22. Mills RM, LeJemtel TH, Horton DP, Liang C, Lang R, Silver MA, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol. 1999;34:155–162
  23. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246–253
  24. Wang DJ, Dowling TC, Meadows D, Ayala T, Marshall J, Minshall S, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004;110:1620–1625
  25. Redfield MM, Edwards BS, Heublein DM, Burnett JC. Restoration of renal response to atrial natriuretic factor in experimental low-output heart failure. Am J Physiol. 1989;257:R917–R923
  26. Riter HG, Redfield MM, Burnett JC, Chen HH. Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol. 2006;47:2334–2335
  27. Mentzer RM, Oz MC, Sladen RN, Graeve AH, Hebeler RF, Luber JM, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial. J Am Coll Cardiol. 2007;49:716–726
  28. Hoffman A, Burnett JC, Haramati A, Winaver J. Effects of atrial natriuretic factor in rats with experimental high-output heart failure. Kidney Int. 1988;33:656–661
  29. Scriven TA, Burnett JC. Effects of synthetic atrial natriuretic peptide on renal function and renin release in acute experimental heart failure. Circulation. 1985;72:892–897
  30. Abraham WT, Lowes BD, Ferguson DA, Odom J, Kim JK, Robertson AD, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4:37–44
  31. Lainchbury JG, Richards AM, Nicholls MG, Hunt PJ, Ikram H, Espiner EA, et al. The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction. Hypertension. 1997;30(3 Pt 1):398–404
  32. Sabrane K, Kruse MN, Fabritz L, Zetsche B, Mitko D, Skryabin BV, et al. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest. 2005;115:1666–1674
  33. De Pasquale CG, Dunne JS, Minson RB, Arnolda LF. Hypotension is associated with diuretic resistance in severe chronic heart failure, independent of renal function. Eur J Heart Fail. 2005;7:888–891
  34. Chen HH, Redfield MM, Nordstrom LJ, Cataliotti A, Burnett JC, Hillege HL, et al. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol Renal Physiol. 2003;284:F1115–F1119
  35. Cuffe MS, Califf RM, Adams KF, Benza R, Bourge R, Colucci WS, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–1547
  36. Peacock WF, Holland R, Gyarmathy R, Dunbar L, Klapholz M, Horton DP, et al. Observation unit treatment of heart failure with nesiritide: results from the proaction trial. J Emerg Med. 2005;29:243–252

 This study was funded in part by a grant from Scios (Mountain View, CA). Funding for Dr. Owan (T32-HL07111) and Drs. Burnett, Chen, and Redfield (P01 HL 76611) is provided in part by the National Institutes of Health.

PII: S1071-9164(07)01161-X

doi: 10.1016/j.cardfail.2007.12.002

Journal of Cardiac Failure
Volume 14, Issue 4 , Pages 267-275 , May 2008

Article Tools

* Image Usage & Resolution